NZ337792A - Nuclear transfer and use in cloning - Google Patents
Nuclear transfer and use in cloningInfo
- Publication number
- NZ337792A NZ337792A NZ337792A NZ33779299A NZ337792A NZ 337792 A NZ337792 A NZ 337792A NZ 337792 A NZ337792 A NZ 337792A NZ 33779299 A NZ33779299 A NZ 33779299A NZ 337792 A NZ337792 A NZ 337792A
- Authority
- NZ
- New Zealand
- Prior art keywords
- cells
- cell
- donor
- human
- cloned
- Prior art date
Links
- 238000012546 transfer Methods 0.000 title claims abstract description 72
- 238000010367 cloning Methods 0.000 title claims description 17
- 210000004027 cell Anatomy 0.000 claims abstract description 385
- 238000000034 method Methods 0.000 claims abstract description 109
- 230000022131 cell cycle Effects 0.000 claims abstract description 84
- 210000001161 mammalian embryo Anatomy 0.000 claims abstract description 52
- 230000002062 proliferating effect Effects 0.000 claims abstract description 24
- 210000004102 animal cell Anatomy 0.000 claims abstract description 4
- 210000002257 embryonic structure Anatomy 0.000 claims description 69
- 238000011161 development Methods 0.000 claims description 55
- 230000018109 developmental process Effects 0.000 claims description 54
- 241000283690 Bos taurus Species 0.000 claims description 39
- 238000000338 in vitro Methods 0.000 claims description 35
- 241001465754 Metazoa Species 0.000 claims description 33
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 30
- 230000003325 follicular Effects 0.000 claims description 27
- 210000000287 oocyte Anatomy 0.000 claims description 26
- 230000009261 transgenic effect Effects 0.000 claims description 26
- 210000001519 tissue Anatomy 0.000 claims description 24
- 230000001360 synchronised effect Effects 0.000 claims description 22
- 230000001605 fetal effect Effects 0.000 claims description 16
- 238000004519 manufacturing process Methods 0.000 claims description 15
- 230000008672 reprogramming Effects 0.000 claims description 15
- 210000000130 stem cell Anatomy 0.000 claims description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 210000002950 fibroblast Anatomy 0.000 claims description 13
- 108090000623 proteins and genes Proteins 0.000 claims description 13
- 238000002054 transplantation Methods 0.000 claims description 13
- 238000011282 treatment Methods 0.000 claims description 13
- 210000001109 blastomere Anatomy 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 10
- 210000000056 organ Anatomy 0.000 claims description 10
- 210000002308 embryonic cell Anatomy 0.000 claims description 9
- 235000013336 milk Nutrition 0.000 claims description 9
- 239000008267 milk Substances 0.000 claims description 9
- 210000004080 milk Anatomy 0.000 claims description 9
- 230000006378 damage Effects 0.000 claims description 8
- 230000002068 genetic effect Effects 0.000 claims description 8
- 238000001727 in vivo Methods 0.000 claims description 8
- 241000124008 Mammalia Species 0.000 claims description 7
- KYRVNWMVYQXFEU-UHFFFAOYSA-N Nocodazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CS1 KYRVNWMVYQXFEU-UHFFFAOYSA-N 0.000 claims description 7
- 229950006344 nocodazole Drugs 0.000 claims description 7
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 230000001225 therapeutic effect Effects 0.000 claims description 7
- NNJPGOLRFBJNIW-HNNXBMFYSA-N (-)-demecolcine Chemical compound C1=C(OC)C(=O)C=C2[C@@H](NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-HNNXBMFYSA-N 0.000 claims description 6
- NNJPGOLRFBJNIW-UHFFFAOYSA-N Demecolcine Natural products C1=C(OC)C(=O)C=C2C(NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-UHFFFAOYSA-N 0.000 claims description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 6
- 241001494479 Pecora Species 0.000 claims description 6
- 208000027418 Wounds and injury Diseases 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 210000005260 human cell Anatomy 0.000 claims description 6
- 208000014674 injury Diseases 0.000 claims description 6
- 241000282472 Canis lupus familiaris Species 0.000 claims description 5
- 241000282994 Cervidae Species 0.000 claims description 5
- 241000283086 Equidae Species 0.000 claims description 5
- 241000282326 Felis catus Species 0.000 claims description 5
- 241000283984 Rodentia Species 0.000 claims description 5
- 238000004113 cell culture Methods 0.000 claims description 5
- 238000003780 insertion Methods 0.000 claims description 5
- 230000037431 insertion Effects 0.000 claims description 5
- 210000002569 neuron Anatomy 0.000 claims description 5
- 241000894007 species Species 0.000 claims description 5
- 238000002689 xenotransplantation Methods 0.000 claims description 5
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- 108700019146 Transgenes Proteins 0.000 claims description 4
- 230000009286 beneficial effect Effects 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 230000004069 differentiation Effects 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 238000007876 drug discovery Methods 0.000 claims description 4
- 230000014509 gene expression Effects 0.000 claims description 4
- 238000001415 gene therapy Methods 0.000 claims description 4
- 235000013372 meat Nutrition 0.000 claims description 4
- 230000004048 modification Effects 0.000 claims description 4
- 238000012986 modification Methods 0.000 claims description 4
- 230000009758 senescence Effects 0.000 claims description 4
- 231100000041 toxicology testing Toxicity 0.000 claims description 4
- 241000283707 Capra Species 0.000 claims description 3
- 241000282412 Homo Species 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 208000012902 Nervous system disease Diseases 0.000 claims description 3
- 208000025966 Neurological disease Diseases 0.000 claims description 3
- 241000288906 Primates Species 0.000 claims description 3
- 241000282887 Suidae Species 0.000 claims description 3
- 208000035475 disorder Diseases 0.000 claims description 3
- 230000000366 juvenile effect Effects 0.000 claims description 3
- 201000006938 muscular dystrophy Diseases 0.000 claims description 3
- 208000020431 spinal cord injury Diseases 0.000 claims description 3
- 241000251468 Actinopterygii Species 0.000 claims description 2
- 241000269328 Amphibia Species 0.000 claims description 2
- 241000271566 Aves Species 0.000 claims description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 claims description 2
- 208000024556 Mendelian disease Diseases 0.000 claims description 2
- 241000607479 Yersinia pestis Species 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 238000009395 breeding Methods 0.000 claims description 2
- 230000001488 breeding effect Effects 0.000 claims description 2
- 230000001413 cellular effect Effects 0.000 claims description 2
- 238000007796 conventional method Methods 0.000 claims description 2
- 238000012217 deletion Methods 0.000 claims description 2
- 230000037430 deletion Effects 0.000 claims description 2
- 230000001419 dependent effect Effects 0.000 claims description 2
- 210000002064 heart cell Anatomy 0.000 claims description 2
- 208000019622 heart disease Diseases 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 210000005229 liver cell Anatomy 0.000 claims description 2
- 210000000663 muscle cell Anatomy 0.000 claims description 2
- 239000002417 nutraceutical Substances 0.000 claims description 2
- 235000021436 nutraceutical agent Nutrition 0.000 claims description 2
- 210000002700 urine Anatomy 0.000 claims description 2
- 238000007380 fibre production Methods 0.000 claims 1
- 210000003292 kidney cell Anatomy 0.000 claims 1
- 210000005265 lung cell Anatomy 0.000 claims 1
- 210000004940 nucleus Anatomy 0.000 description 49
- 239000002609 medium Substances 0.000 description 34
- 230000004927 fusion Effects 0.000 description 25
- 230000000694 effects Effects 0.000 description 24
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 23
- 239000012894 fetal calf serum Substances 0.000 description 23
- 230000004913 activation Effects 0.000 description 22
- 210000002459 blastocyst Anatomy 0.000 description 21
- 210000002966 serum Anatomy 0.000 description 20
- 230000004083 survival effect Effects 0.000 description 17
- BVIAOQMSVZHOJM-UHFFFAOYSA-N N(6),N(6)-dimethyladenine Chemical compound CN(C)C1=NC=NC2=C1N=CN2 BVIAOQMSVZHOJM-UHFFFAOYSA-N 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 15
- 230000011278 mitosis Effects 0.000 description 15
- 238000005516 engineering process Methods 0.000 description 14
- 230000018199 S phase Effects 0.000 description 13
- 244000309466 calf Species 0.000 description 13
- 230000035935 pregnancy Effects 0.000 description 13
- 210000001626 skin fibroblast Anatomy 0.000 description 13
- 230000010190 G1 phase Effects 0.000 description 12
- 210000000805 cytoplasm Anatomy 0.000 description 12
- 108010077544 Chromatin Proteins 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 10
- 210000003483 chromatin Anatomy 0.000 description 10
- 210000004748 cultured cell Anatomy 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 230000035800 maturation Effects 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 238000013459 approach Methods 0.000 description 7
- 230000013020 embryo development Effects 0.000 description 7
- 210000003754 fetus Anatomy 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 230000000394 mitotic effect Effects 0.000 description 7
- 108010076119 Caseins Proteins 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
- 102000011632 Caseins Human genes 0.000 description 5
- 239000007995 HEPES buffer Substances 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 229910052791 calcium Inorganic materials 0.000 description 5
- 239000005018 casein Substances 0.000 description 5
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 5
- 235000021240 caseins Nutrition 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 4
- 230000006820 DNA synthesis Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 210000000349 chromosome Anatomy 0.000 description 4
- 230000001086 cytosolic effect Effects 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 244000144972 livestock Species 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 210000001082 somatic cell Anatomy 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 230000007910 cell fusion Effects 0.000 description 3
- 230000007159 enucleation Effects 0.000 description 3
- 238000012239 gene modification Methods 0.000 description 3
- 238000010353 genetic engineering Methods 0.000 description 3
- 230000005017 genetic modification Effects 0.000 description 3
- 235000013617 genetically modified food Nutrition 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000000984 immunochemical effect Effects 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 3
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 3
- 229940043355 kinase inhibitor Drugs 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 210000000633 nuclear envelope Anatomy 0.000 description 3
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 3
- 239000003104 tissue culture media Substances 0.000 description 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 2
- 229940123587 Cell cycle inhibitor Drugs 0.000 description 2
- 108050006400 Cyclin Proteins 0.000 description 2
- 230000027311 M phase Effects 0.000 description 2
- 102000011961 Maturation-Promoting Factor Human genes 0.000 description 2
- 108010075942 Maturation-Promoting Factor Proteins 0.000 description 2
- 241000283903 Ovis aries Species 0.000 description 2
- 239000005662 Paraffin oil Substances 0.000 description 2
- 102000009339 Proliferating Cell Nuclear Antigen Human genes 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- GBOGMAARMMDZGR-UHFFFAOYSA-N UNPD149280 Natural products N1C(=O)C23OC(=O)C=CC(O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 GBOGMAARMMDZGR-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000004413 cardiac myocyte Anatomy 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 230000001351 cycling effect Effects 0.000 description 2
- GBOGMAARMMDZGR-JREHFAHYSA-N cytochalasin B Natural products C[C@H]1CCC[C@@H](O)C=CC(=O)O[C@@]23[C@H](C=CC1)[C@H](O)C(=C)[C@@H](C)[C@@H]2[C@H](Cc4ccccc4)NC3=O GBOGMAARMMDZGR-JREHFAHYSA-N 0.000 description 2
- GBOGMAARMMDZGR-TYHYBEHESA-N cytochalasin B Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@@H]3/C=C/C[C@H](C)CCC[C@@H](O)/C=C/C(=O)O[C@@]23C(=O)N1)=C)C)C1=CC=CC=C1 GBOGMAARMMDZGR-TYHYBEHESA-N 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 244000144992 flock Species 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 210000004524 haematopoietic cell Anatomy 0.000 description 2
- 244000309465 heifer Species 0.000 description 2
- 244000144980 herd Species 0.000 description 2
- 235000003642 hunger Nutrition 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000031864 metaphase Effects 0.000 description 2
- 210000003101 oviduct Anatomy 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000037351 starvation Effects 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000016853 telophase Effects 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 108091060290 Chromatid Proteins 0.000 description 1
- 206010008805 Chromosomal abnormalities Diseases 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 1
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 1
- 102000004654 Cyclic GMP-Dependent Protein Kinases Human genes 0.000 description 1
- 108010003591 Cyclic GMP-Dependent Protein Kinases Proteins 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 238000012270 DNA recombination Methods 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108010069091 Dystrophin Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 1
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000012271 agricultural production Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000031016 anaphase Effects 0.000 description 1
- NOFOAYPPHIUXJR-APNQCZIXSA-N aphidicolin Chemical compound C1[C@@]23[C@@]4(C)CC[C@@H](O)[C@@](C)(CO)[C@@H]4CC[C@H]3C[C@H]1[C@](CO)(O)CC2 NOFOAYPPHIUXJR-APNQCZIXSA-N 0.000 description 1
- SEKZNWAQALMJNH-YZUCACDQSA-N aphidicolin Natural products C[C@]1(CO)CC[C@]23C[C@H]1C[C@@H]2CC[C@H]4[C@](C)(CO)[C@H](O)CC[C@]34C SEKZNWAQALMJNH-YZUCACDQSA-N 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000004756 chromatid Anatomy 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- OOTFVKOQINZBBF-UHFFFAOYSA-N cystamine Chemical compound CCSSCCN OOTFVKOQINZBBF-UHFFFAOYSA-N 0.000 description 1
- 229940099500 cystamine Drugs 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000008143 early embryonic development Effects 0.000 description 1
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 210000002503 granulosa cell Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 210000004754 hybrid cell Anatomy 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 210000000472 morula Anatomy 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 230000003094 perturbing effect Effects 0.000 description 1
- 210000004508 polar body Anatomy 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000035752 proliferative phase Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 1
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000013337 sub-cultivation Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 210000004367 thymic lymphocyte Anatomy 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 210000004340 zona pellucida Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/873—Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N2502/1323—Adult fibroblasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2517/00—Cells related to new breeds of animals
- C12N2517/10—Conditioning of cells for in vitro fecondation or nuclear transfer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Neurology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Neurosurgery (AREA)
- General Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Developmental Biology & Embryology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
Priority Applications (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ337792A NZ337792A (en) | 1999-09-14 | 1999-09-14 | Nuclear transfer and use in cloning |
| CN00813845A CN1424870A (zh) | 1999-09-14 | 2000-09-14 | 用挑选的供体细胞实施核移植 |
| JP2001522836A JP2004500038A (ja) | 1999-09-14 | 2000-09-14 | 選択したドナー細胞を用いる核移植 |
| AU74624/00A AU784371B2 (en) | 1999-09-14 | 2000-09-14 | Nuclear transfer with selected donor cells |
| ARP000104816A AR032284A1 (es) | 1999-09-14 | 2000-09-14 | Transferencia nuclear con celulas donantes seleccionadas |
| PCT/NZ2000/000179 WO2001019182A1 (fr) | 1999-09-14 | 2000-09-14 | Transfert nucleaire utilisant des cellules donneuses selectionnees |
| DE10084987T DE10084987T1 (de) | 1999-09-14 | 2000-09-14 | Nukleärertransfer mit ausgewählten Spenderzellen |
| GB0205915A GB2369828B (en) | 1999-09-14 | 2000-09-14 | Nuclear transfer with selected donor cells |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ337792A NZ337792A (en) | 1999-09-14 | 1999-09-14 | Nuclear transfer and use in cloning |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ337792A true NZ337792A (en) | 2002-03-28 |
Family
ID=19927507
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ337792A NZ337792A (en) | 1999-09-14 | 1999-09-14 | Nuclear transfer and use in cloning |
Country Status (8)
| Country | Link |
|---|---|
| JP (1) | JP2004500038A (fr) |
| CN (1) | CN1424870A (fr) |
| AR (1) | AR032284A1 (fr) |
| AU (1) | AU784371B2 (fr) |
| DE (1) | DE10084987T1 (fr) |
| GB (1) | GB2369828B (fr) |
| NZ (1) | NZ337792A (fr) |
| WO (1) | WO2001019182A1 (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7122177B2 (en) | 2000-01-20 | 2006-10-17 | Diabcell Pty Ltd. | Preparation and xenotransplantation of porcine islets |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2509465A1 (fr) * | 2002-12-10 | 2004-06-24 | Gtc Biotherapeutics, Inc. | Procede et systeme d'utilisation d'embryons de transfert nucleaire cellulaire de cellule somatique en tant que donneurs de cellules pour un transfert nucleaire supplementaire |
| JP2006081542A (ja) * | 2004-08-18 | 2006-03-30 | Institute Of Physical & Chemical Research | クローン哺乳動物の作成方法 |
| JP2010075099A (ja) * | 2008-09-26 | 2010-04-08 | Japan Science & Technology Agency | 哺乳動物核移植胚のスクリーニング方法、非ヒト哺乳動物核移植胚、クローン非ヒト哺乳動物、及びスクリーニングキット |
| WO2016036754A1 (fr) * | 2014-09-02 | 2016-03-10 | The Regents Of The University Of California | Procédés et compositions pour assurer la modification de l'adn cible arn dépendante |
| CN105483216B (zh) * | 2015-11-30 | 2019-01-15 | 四川农业大学 | 一种家兔cetp基因检测肉质育种的方法 |
| CN108624621B (zh) * | 2018-01-17 | 2019-04-12 | 中国科学院上海生命科学研究院 | 非人灵长类的体细胞克隆动物的制备方法 |
| MX2022011245A (es) | 2020-03-11 | 2023-01-11 | Bit Bio Ltd | Método de generación de células hepáticas. |
| CN111793671A (zh) * | 2020-07-22 | 2020-10-20 | 中国农业大学 | 一种优化的适用于绵羊染色体二元流式分选的染色体悬液制备方法 |
| CN112715479A (zh) * | 2021-01-06 | 2021-04-30 | 吉沙阿牛 | 一种山羊生态循环养殖方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999046982A1 (fr) * | 1998-03-16 | 1999-09-23 | Relag Pty Ltd | Transfert de noyau de cellules porcines |
-
1999
- 1999-09-14 NZ NZ337792A patent/NZ337792A/en not_active IP Right Cessation
-
2000
- 2000-09-14 AU AU74624/00A patent/AU784371B2/en not_active Ceased
- 2000-09-14 CN CN00813845A patent/CN1424870A/zh active Pending
- 2000-09-14 JP JP2001522836A patent/JP2004500038A/ja active Pending
- 2000-09-14 AR ARP000104816A patent/AR032284A1/es unknown
- 2000-09-14 GB GB0205915A patent/GB2369828B/en not_active Expired - Fee Related
- 2000-09-14 WO PCT/NZ2000/000179 patent/WO2001019182A1/fr active Application Filing
- 2000-09-14 DE DE10084987T patent/DE10084987T1/de not_active Withdrawn
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7122177B2 (en) | 2000-01-20 | 2006-10-17 | Diabcell Pty Ltd. | Preparation and xenotransplantation of porcine islets |
| US8142769B2 (en) | 2000-01-20 | 2012-03-27 | Diabcell Pty Ltd | Preparation and xenotransplantation of porcine islets |
Also Published As
| Publication number | Publication date |
|---|---|
| AU7462400A (en) | 2001-04-17 |
| CN1424870A (zh) | 2003-06-18 |
| GB0205915D0 (en) | 2002-04-24 |
| GB2369828B (en) | 2004-12-01 |
| DE10084987T1 (de) | 2003-04-17 |
| JP2004500038A (ja) | 2004-01-08 |
| AU784371B2 (en) | 2006-03-23 |
| AR032284A1 (es) | 2003-11-05 |
| WO2001019182A1 (fr) | 2001-03-22 |
| GB2369828A (en) | 2002-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1248288B (zh) | 用分化胎儿和成年供体细胞进行的核转移 | |
| US6215041B1 (en) | Cloning using donor nuclei from a non-quiesecent somatic cells | |
| US6235969B1 (en) | Cloning pigs using donor nuclei from non-quiescent differentiated cells | |
| US7371922B2 (en) | Nuclear transfer with porcine embryonic stem cells | |
| EP1017422A1 (fr) | Clonage a l'aide de noyaux donneurs a partir de cellules differentiees ne presentant pas de carence serique | |
| Galli et al. | Introduction to cloning by nuclear transplantation | |
| US20050074439A1 (en) | Cloned ungulate embryos and animals, use of cells, tissues and organs thereof for transplantation therapies including Parkinson's disease | |
| AU784371B2 (en) | Nuclear transfer with selected donor cells | |
| US20010039667A1 (en) | Cloned ungulate embryos and animals, use of cells, tissues and organs thereof for transplantation therapies including parkinson's disease | |
| Eyestone et al. | Nuclear transfer from somatic cells: applications in farm animal species | |
| US20050149999A1 (en) | Methods for cloning mammals using remodeling factors | |
| US20030101469A1 (en) | Cloned non-human mammals from contact inhibited donor cells | |
| US20040077077A1 (en) | Novel methods for the production of cloned mammals, mammals cloned according to the methods, and methods of use of same | |
| MXPA02010075A (es) | Celulas pluripotentes que comprenden nucleos alogenicos y mitocondria. | |
| US20120076761A1 (en) | Cloned ungulate embryos and animals, use of cells, tissues and organs thereof for transplantation therapies including Parkinson's disease | |
| Reggio | Production of transgenic goats by somatic cell nuclear transfer | |
| Chesné et al. | Cloning in the rabbit: present situation and prospects | |
| Landry | Reconstruction of nuclear transfer embryos in goats and cattle [electronic resource] | |
| Stice | Cloning using donor nuclei from a non-quiesecent somatic cells | |
| Chen | Manipulation of oocyte maturation to improve porcine somatic cell nuclear transfer | |
| MXPA99006464A (en) | Nuclear transfer with differentiated fetal and adult donor cells | |
| AU2006202185A1 (en) | Cloning using donor nuclei from non-serum starved, differentiated cells | |
| MXPA00000201A (en) | Cloning using donor nuclei from non-serum starved, differentiated cells | |
| AU2011202964A1 (en) | Nuclear transfer with differentiated fetal and adult donor cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 7 YEARS UNTIL 14 SEP 2020 BY AJ PARK Effective date: 20130815 |
|
| EXPY | Patent expired |